在晚期和耐火性皮肤状细胞癌中,抗EGFR加抗PD1:一个队列研究
Camille Guy1, Candice Hober1, Sophie Maiezza1
1Univ. Lille, CHU Lille, Service de Dermatologie, F-59000, Lille, France.
The oncologist
|March 14, 2026
概括
抗编程死亡1 (anti-PD1) 和抗表皮生长因子受体 (anti-EGFR) 疗法的组合在先进的皮肤状细胞癌 (cSCC) 患者中显示出有希望的疗效,这些患者先前接受过免疫治疗. 这种后续策略在现实环境中证明了临床活性,具有可管理的副作用.
科学领域:
- 皮肤瘤学 皮肤瘤学
- 医学瘤学 医学瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 晚期皮肤状细胞癌 (cSCC) 的预后不好.
- 抗PD1免疫疗法改善了cSCC治疗,但存在局限性.
- 像抗EGFR抗体和化疗等二线疗法提供暂时的疗效.
研究的目的:
- 评估结合抗PD1和抗EGFR药物的疗效和安全性,用于高级cSCC.
- 评估这种组合作为第二线或第三线治疗对抗PD1单一治疗不耐药的患者.
主要方法:
- 追溯的,单心的队列研究.
- 包括14名在2013年至2024年期间接受治疗的晚期cSCC患者.
- 在抗PD1失败后接受抗PD1/抗EGFR组合治疗的患者的分析.
主要成果:
- 总体响应率为38.5% (15.5%完全/持久,23%部分).
- 观察到早期反应,两名患者的反应加深.
- 主要是1级不良事件;只有2例3级毒性 (状皮疹).
结论:
- 抗PD1/抗EGFR组合在严重预治疗的高级cSCC中显示出临床活性.
- 这种组合是一种可行的后续战略,具有可接受的安全性.
- 支持用于耐火性cSCC的联合免疫疗法和抗EGFR药物的使用.
相关概念视频
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Skin Cancer
5.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K


